| Literature DB >> 22971006 |
Carolina Fernández-Costa1, Valentina Calamia, Patricia Fernández-Puente, José-Luis Capelo-Martínez, Cristina Ruiz-Romero, Francisco J Blanco.
Abstract
BACKGROUND: The field of biomarker discovery, development and application has been the subject of intense interest and activity, especially with the recent emergence of new technologies, such as proteomics-based approaches. In proteomics, search for biomarkers in biological fluids such as human serum is a challenging issue, mainly due to the high dynamic range of proteins present in these types of samples. Methods for reducing the content of most highly abundant proteins have been developed, including immunodepletion or protein equalization. In this work, we report for the first time the combination of a chemical sequential depletion method based in two protein precipitations with acetonitrile and DTT, with a subsequent two-dimensional difference in-gel electrophoresis (2D-DIGE) analysis for the search of osteoarthritis (OA) biomarkers in human serum. The depletion method proposed is non-expensive, of easy implementation and allows fast sample throughput.Entities:
Year: 2012 PMID: 22971006 PMCID: PMC3515479 DOI: 10.1186/1477-5956-10-55
Source DB: PubMed Journal: Proteome Sci ISSN: 1477-5956 Impact factor: 2.480
Figure 1Workflow of the strategy performed for the DIGE-based quantitative differential proteomic analysis on human sera.
Figure 2Reproducibility of the sequential depletion method. Technical (A) and biological (B) replicates were analyzed by MALDI-TOF/TOF MS in order to evaluate the reproducibility. Coloured squares show the identification of each protein on the different replicates. (C) SDS-PAGE gel (10% acrylamide, silver staining), illustrating the representative protein profiles obtained after the sequential depletion of three independent sera by duplicate, which further demonstrate the reproducibility of the strategy.
Figure 3Differential protein profile of sequentially depleted serum. One-dimensional (A) and two-dimensional (B) gel electrophoresis separations, showing the different protein profiles of non-depleted human serum (ND) and serum depleted (D) according to the sequential method presented in this work. Some of the most representative proteins that are either depleted or typically present in the depleted maps are depicted. A1AT: alpha-1-antitrypsin; A2MG: alpha-2-macroglobulin; ALBU: serum albumin; APOA1: apolipoprotein A1; APOC3: apolipoprotein C3; CO3α: complement factor α; HPT: haptoglobin; IGGγ: IgG heavy (gamma) chain; IGGκ/λ: IgG light (kappa/lambda) chains; TRFE: transferrin; TTYH: transthyretin. In (C), this protein profile is compared to those obtained with ACN and DTT protein depletion methods alone. 1: crude serum, 2: ACN depletion, 3: DTT depletion, 4: sequential depletion.
Characteristics of the osteoarthritis (OA) patients and controls included in this study
| Number of patients | 20 | 20 |
| Agea) | 67.75 ± 9.08 | 75.85 ± 5.00 |
| Proteinb) | 57.68 ± 5.06 | 56.38 ± 4.92 |
| | ||
| Number of patients | 10 | 10 |
| Age | 66.20 ± 8.83 | 76.10 ± 4.79 |
| Protein | 57.69 ± 5.15 | 54.69 ± 4.50 |
| | ||
| Number of patients | 10 | 10 |
| Age | 69.30 ± 9.52 | 75.60 ± 5.44 |
| Protein | 57.66 ± 5.25 | 58.07 ± 3.83 |
a) Age shown as years with mean ± SD.
b) Protein shown in μg/μl with mean ± SD.
DIGE experimental design
| Pool 1/Cy3 | Pool 2/Cy5 | |
| Pool 1/Cy5 | Pool 2/Cy3 | |
| Pool 3/Cy3 | Pool 4/Cy5 | |
| Pool 3/Cy5 | Pool 4/Cy3 |
Figure 4Images from the DIGE gels obtained in this work. The two-dimensional gel images corresponding to the Cy2-, Cy3- and Cy5-labeled samples are shown.
Figure 5Two-dimensional gel showing the putative OA protein biomarkers identified in this work. Protein abbreviations, according to Table 3.
Proteins identified in this work as altered in Osteoarthritis vs Control sera
| A1AT | P01009 | Alpha-1-antitrypsin | Inhibitor of serine proteases | 1.4 | 0.008 | 46878 | 5.37 | 40047 | 5.33 | 151 | K. TDTSHHDQDHPTFNK.I |
| | | | | | | | | | | | K. ITPNLAEFAFSLYR.Q |
| | | | | | | | | | | | K. QINDYVEKGTQGK.I |
| | | | | | | | | | | | K. GKWERPFEVK.D |
| | | | | | | | | | | | K. DTEEEDFHVDQVTTVK.V |
| | | | | | | | | | | | R. LGMFNIQHCK.K |
| | | | | | | | | | | | K. LQHLENELTHDIITK.F |
| | | | | | | | | | | | K. FLENEDRR.S |
| | | | | | | | | | | | K. VFSNGADLSGVTEEAPLK.L |
| | | | | | | | | | | | K. FNKPFVFLMIEQNTK.S |
| FETUA | P02765 | Alpha-2-HS-glycoprotein | Negative regulation of bone mineralization | 2 | 0.004 | 40098 | 5.43 | 40098 | 5.43 | 102 | K. CNLLAEKQYGFCK.A |
| | | | | | | | R. HTFMGVVSLGSPSGEVSHPR.K | ||||
| ANGT | P01019 | Angiotensinogen | Essential component of the renin-angiotensin system (RAS) | 1.3 | 0.001 | 53406 | 5.87 | 40056 | 5.48 | 28 | K. ANAGKPKDPTFIPAPIQAK.T |
| APOA1 | P02647 | Apolipoprotein A-I | Cholesterol metabolism | 2.2 | 0.013 | 30759 | 5.56 | 31221 | 5.43 | 271 | K. DSGRDYVSQFEGSALGK.Q |
| | | | | | | | | | | | K. LLDNWDSVTSTFSK.L |
| | | | | | | | | | | | K. LLDNWDSVTSTFSKLR.E |
| | | | | | | | | | | | K. VQPYLDDFQKK.W |
| | | | | | | | | | | | K. KWQEEMELYR.Q |
| | | | | | | | | | | | K. WQEEMELYR.Q |
| | | | | | | | | | | | K. VEPLRAELQEGAR.Q |
| | | | | | | | | | | | K. LSPLGEEMRDR.A |
| | | | | | | | | | | | R. THLAPYSDELR.Q |
| | | | | | | | | | | | R. THLAPYSDELRQR.L |
| | | | | | | | | | | | K. ATEHLSTLSEKAKPALEDLR.Q |
| | | | | | | | | | | | K. AKPALEDLR.Q |
| APOA2 | P02652 | Apolipoprotein A-II | Lipid transport | 0.7 | 0.003 | 11282 | 6.26 | 11064 | 5.23 | 82 | K. VKSPELQAEAK.S |
| | | | | | | | | | | | K. SPELQAEAK.S |
| | | | | | | | | | | | K. SKEQLTPLIK.K |
| APOA4 | P06727 | Apolipoprotein A-IV | Lipid transport | 0.6 | 0.005 | 45371 | 5.28 | 37738 | 5.47 | 37 | K. LVPFATELHER.L |
| | | | | | | | | | | | R. LEPYADQLR.T |
| | | | | | | | | | | | R. TQVNTQAEQLRR.Q |
| | | | | | | | | | | | R. QLTPYAQR.M |
| | | | | | | | | | | | K. IDQNVEELKGR.L |
| | | | | | | | | | | | R. ISASAEELRQR.L |
| | | | | | | | | | | | R. LAPLAEDVR.G |
| | | | | | | | | | | | R. LAPLAEDVRGNLR.G |
| | | | | | | | | | | | K. SLAELGGHLDQQVEEFR.R |
| | | | | | | | | | | | K. SLAELGGHLDQQVEEFRR.R |
| | | | | | | | | | | | R. RVEPYGENFNK.A |
| | | | | | | | | | | | K. ALVQQMEQLR.Q |
| APOC3 | P02656 | Apolipoprotein C-III | Lipid degradation and transport | 0.8 | 0.014 | 10846 | 5.23 | 13922 | 5.16 | 149 | K. TAKDALSSVQESQVAQQAR.G |
| | | | | | | | | | | K. DALSSVQESQVAQQAR.G | |
| HPT | P00738 | Haptoglobin (β chain) | Cellular iron ion homeostasis | 2 | 0.007 | 45861 | 6.13 | 35377 | 5.74 | 90 | K. GSFPWQAK.M |
| | | | | | | | R. NANFKFTDHLK.Y | ||||
| | | | | | | | | | | | K. YVMLPVADQDQCIR.H |
| | | | | | | | | | | | K. SPVGVQPILNEHTFCAGMSK.Y |
| HPT | P00738 | Haptoglobin (α 1 chain) | Cellular iron ion homeostasis | 1.4 | 0.006 | 45861 | 6.13 | 19281 | 5.98 | 68 | R. YQCKNYYK.L |
| | | | | | | | K. LRTEGDGVYTLNNEK.Q | ||||
| | | | | | | | | | | | K. AVGDKLPECEAVCGKPK.N |
| HPT | P00738 | Haptoglobin (α 2 chain) | Cellular iron ion homeostasis | 0.5 | 0.0002 | 45861 | 6.13 | 28110 | 5.97 | 135 | R. TEGDGVYTLNDKK.Q |
| | | | | | | | K. LRTEGDGVYTLNNEK.Q | ||||
| | | | | | | | | | | | K. AVGDKLPECEAVCGKPK.N |
| | | | | | | | | | | | K. AVGDKLPECEAVCGKPK.N |
| HBB | P68871 | Hemoglobin subunit beta | Involved in oxygen transport from the lung to peripheral tissues | 1.6 | 0.014 | 16102 | 6.75 | 16102 | 6.75 | 43 | R. LLVVYPWTQR.F |
| IGKC | P01834 | Ig kappa chain C region | Immune response | 0.6 | 0.003 | 11773 | 5.58 | 33273 | 6.42 | 107 | -. TVAAPSVFIFPPSDEQLK.S |
| | | | | | | | | | | | K. SGTASVVCLLNNFYPR.E |
| LAC2 | P0CG05 | Ig lambda-2 chain C regions | Complement activation, classical pathway | 0.6 | 0.003 | 11458 | 6.92 | 33273 | 6.42 | 72 | K. AAPSVTLFPPSSEELQANK.A |
| | | | | | | | K. QSNNKYAASSYLSLTPEQWK.S | ||||
| | | | | | | | | | | | R. SYSCQVTHEGSTVEK.T |
| | | | | | | | | | | | R. SYSCQVTHEGSTVEKTVAPTECS.- |
| A2GL | P02750 | Leucine-rich alpha-2-glycoprotein | Protein binding (secreted) | 1.5 | 0.005 | 38382 | 6.45 | 38507 | 5.47 | 88 | R. YLFLNGNKLAR.V |
| | | | | | | | R. VAAGAFQGLR.Q | ||||
| | | | | | | | | | | | R. CAGPEAVKGQTLLAVAK.S |
| SAA | P02735 | Serum amyloid A protein | Acute-phase response | 0.8 | 0.014 | 13581 | 6.28 | 15299 | 6.53 | 52 | R.EANYIGSDKYFHAR.G |
| | | | | | | | | | | | R.FFGHGAEDSLADQAANEWGR.S |
| TTHY | P02766 | Transthyretin | Thyroid hormone-binding protein | 2.2 | 0.022 | 15991 | 5.52 | 28287 | 6.3 | 136 | R.KAADDTWEPFASGK.T |
| K.AADDTWEPFASGK.T | |||||||||||
a) Protein ID and accession number according to SwissProt database.
b) Average volume ratio OA:N, quantified by SameSpots software.
c) Predicted molecular weight (MW) and Isoelectric point (pI) according to protein sequence and SwissProt database.
d) Experimental molecular weight (MW) and Isoelectric point (pI) calculated by analysis of the gel images with SameSpots software.
e) MS protein score obtained from MALDI-TOF/TOF spectra using Mascot search engine.
f) Sequence tags identified by MALDI-TOF/TOF MS/MS.
Figure 6Verification of the OA-dependent alteration of HPT by Western blot analyses of independent samples. (A) Representative image obtained from the DIGE gels, together with the quantitative data acquired thereof for Haptoglobin beta chain (HPT, which was increased in OA samples). (B) Proteins in crude serum samples from OA patients (n = 15) and controls (N, n = 15) were resolved by SDS-PAGE and probed with antibodies against HPT. Band intensities were normalized against the intensity of Ponceau staining (upper figure). (C) Semi-quantitative densitometric analysis of the blot signals confirmed the increase of HPT beta chain in OA sera.